Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 OCT 19 ... Cancerologie Thoracique-0401 phase 11 trial aimed to evaluate the efficacy and safety of gefitinib as a first-line treatment for patients with adenocarcinoma with bronchioloalveolar ...
2009 NOV 2 ... per-residue footprint analysis to characterize binding of three inhibitors (erlotinib, gefitinib, and AEE788) with wildtype EGFR and three mutants. The goal is to characterize how ...
2009 NOV 1 ... by X-rays. Moreover, the cell growth curve and survival curve were down-regulated in the gefitinib-treated groups after irradiation. Meanwhile, the radiation-induced apoptosis of tumor ...
2009 OCT 19 ... to 50% of nonsmoker lung cancer, are positively correlated with responsiveness to gefitinib, and inversely correlated with smoking history." "Activating EGFR ...
2009 NOV 16 ... 2009), using the terms epidermal growth factor receptor inhibitor, cetuximab, erlotinib, gefitinib, panitumumab, management, Skin toxicity, and cutaneous effects." "In ...
2009 NOV 2 ... calcitriol administered in combination with a fixed oral dose of dexamethasone and gefitinib in patients with refractory solid tumors. A fixed oral dose of dexamethasone of 4 mg/day ...
2009 OCT 19 ... "Eighty-three patients with lung adenocarcinoma treated with erlotinib or gefitinib were included in this study. The mutational status of KRAS and EGFR was investigated by ...
2009 NOV 2 ... publish new data in the report 'Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell ...
2009 OCT 19 ... = 0.007). Furthermore, there was a significant difference in therapeutic efficacies of gefitinib between patients with nuclear YB-1 expression and those with non-nuclear YB-1 expression ...
2009 NOV 16 ... Current study results from the report, 'Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer,' ...
2009 OCT 19 ... alone had moderate inhibitory effects on cell viability. However, its combination with gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, induced supra-additive effects in ...
2009 OCT 5 ... dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment,' are discussed in a new report. According to a study from Okayama, Japan, ...
2009 OCT 19 ... focused on 21 female patients with advanced/metastatic lung adenocarcinoma who received gefitinib 250 mg/day (expanded access) or erlotinib 150 mg/die as second/third-line therapy; ...
2009 OCT 5 ... efficacy and safety of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib treatment. with advanced or metastatic NSCLC, who had progressed after...
2009 OCT 19 ... analyses after treatment with various drugs (EGF, celecoxib, prostaglandin E-2, gefitinib, Ro-31-8425, PD98059, and SP600125) in HCT-116-Mock versus HCT-116-COX-2 cells and ...
